 This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 ingenol mebutate Gel, 0.05 will be safe and tolerable in patients with superficial Basal Cell Carcinoma sBCC lesions on the trunk and extremities. 